IDEXX LABORATORIES INC /DE
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.3B | $3.9B | $3.7B | $3.4B | $3.2B |
| Cost of revenue | $1.6B | $1.5B | $1.5B | $1.4B | $1.3B |
| Gross profit | $2.7B | $2.4B | $2.2B | $2.0B | $1.9B |
| Research and development | $251.2M | $219.8M | $191.0M | $254.8M | $161.0M |
| Operating expenses | $1.3B | $1.3B | $1.1B | $1.1B | — |
| Operating income | $1.4B | $1.1B | $1.1B | $898.8M | $932.0M |
| Interest expense | $38.9M | $31.2M | $41.6M | $39.9M | $29.8M |
| Pretax income | $1.3B | $1.1B | $1.1B | $860.0M | $902.7M |
| Income tax expense | $264.7M | $222.0M | $216.1M | $180.9M | $157.8M |
| Net income | $1.1B | $887.9M | $845.0M | $679.1M | $744.8M |
| Balance Sheet | |||||
| Cash and equivalents | $180.1M | $288.3M | $453.9M | $112.5M | $144.5M |
| Current assets | $1.4B | $1.4B | $1.5B | $1.1B | $955.7M |
| Total assets | $3.4B | $3.3B | $3.3B | $2.7B | $2.4B |
| Current liabilities | $1.1B | $1.1B | $951.5M | $1.2B | $763.6M |
| Total liabilities | $1.7B | $1.7B | $1.8B | $2.1B | $1.7B |
| Stockholders' equity | $1.6B | $1.6B | $1.5B | $608.7M | $690.0M |
| Cash Flow Statement | |||||
| Cash from operations | $1.2B | $929.0M | $906.5M | $543.0M | $755.5M |
| Depreciation and amortization | $145.2M | $129.9M | $114.9M | $111.9M | $104.6M |
| Stock-based compensation | $60.0M | $60.3M | $59.7M | $49.8M | $37.8M |
| Capital expenditure | $124.7M | $120.9M | $133.6M | $148.8M | $119.5M |
| Free cash flow | $1.1B | $808.1M | $772.9M | $394.1M | $636.0M |
| Share repurchases | $1.2B | $837.0M | $71.9M | $819.7M | $746.8M |
| Impairments | $0 | $250,000 | $1.5M | $2.3M | $5.1M |
Shares outstanding 78.9M · Free float 99.2%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.